Table 3
From the following article
Chinese health biotech and the billion-patient market
Sarah E Frew, Stephen M Sammut, Alysha F Shore, Joshua K Ramjist, Sara Al-Bader, Rahim Rezaie, Abdallah S Daar & Peter A Singer
Nature Biotechnology 26, 37 - 53 (2008)
doi:10.1038/nbt0108-37
Table 3. Alliances/collaborations between companies interviewed and domestic organizations
| Company name | Chinese collaboration and objective |
|---|---|
| Beijing Wantai Biological Pharmacy Enterprise | Collaborations with Cell Engineering Tumor Cell Laboratory (Xiamen University, China) to produce recombinant HEV antigens; with Xiamen University to produce HIV testing reagent; and with Military Medical Science College (Beijing), details of which have not been disclosed. |
| Bio-Bridge Science | Distribution agreement with Xinhua Surgical Instrument (Shandong, China) to sell surgical instruments in the United States. Cooperative agreements with Chinese Academy of Medical Sciences (Beijing) and the Institute of Basic Medical Sciences to develop human papillomavirus polyvalent vaccine and with the Beijing Institute of Radiation Medicine (Beijing) to conduct pre-clinical study for HIV-papillomavirus vaccine. |
| CapitalBio | Joint product developments with Chinese Center of Disease Control (Beijing) and Beijing Entry-Exit Inspection and Quarantine Bureau (Beijing). Research collaborations with the Chinese Academy of Medical Sciences (Beijing), Tsinghua University (Beijing) and Peking University Hospitals (Beijing), Jilin University (Changchun, China) and Chinese Academy of Sciences (CAS; Beijing). Collaborations with Miaoxiang Sanqi TCM (Wenshan, China) to create cGMP TCM production management system application and with China Medicinal Biotechnology Association, Biochip Branch (Beijing), to create industry standard. |
| HD Biosciences | Collaborating with Sundia MediTech (Shanghai) on structure–activity relationship research and marketing and with United PharmaTech (Shanghai) on active pharmaceutical ingredient production. |
| Shanghai Fudan-Yueda Bio-Tech | Technical support from Key Laboratory of Medical Molecular Virology (Fudan University-Shanghai). Agreement with Cell Star (Shanghai) for development and marketing in China of recombinant human tumor necrosis factor for oncology. R&D product development partnership with Beijing Biological Product Institute (Beijing). |
| Shanghai Genomics | Educational partnership with Shanghai Jiao Tong University (Shanghai), which allows students to obtain PhD while working with company. Collaborations with Chinese National Human Genome Center (Beijing) and Chinese National Human Genome Center at Shanghai (Shanghai). |
| Shanghai Genon Bio-Engineering | Collaborations with Tongji University (Shanghai) and China Pharmaceutical University (Nanjing, China). |
| Shanghai Huaguan Biochip | Collaborations with Shanghai Institutes for Biological Sciences (Shanghai) and Shanghai Institute of Microsystem and Information Technology (Shanghai). |
| Shanghai Sunway Biotech | Collaborating with Sun Yat-Sen University Cancer Center (Guangzhou, China) to run phase 1–3 clinical trials of H101 for head-and-neck squamous cell carcinoma and with Tumor Hospital of Medical Sciences Academy of China (Beijing) to run phase 1 clinical trial of H103 in cancer. Developing gene therapies with Peking Union Medical College Hospital (Beijing), Zhongshan Hospital of Fudan University (Shanghai) and Renji Hospital of Shanghai Jiaotong University (Shanghai) for treatment of peripheral artery disease. |
| Shanghai United Cell Biotech | Developing Genheal (recombinant human growth hormone) with the Institute of Cell Biology (Shanghai). Developing OraVacs with the Academy of Military Medical Sciences (Beijing). |
| Shenzhen Beike Biotechnologies | Clinical/research collaborations with Peking University (Beijing), Hong Kong University of Science and Technology (Hong Kong), Zhengzhou University (Zhengzhou, China) and Shenzhen Graduate School of Qinghua University (Shenzhen, China). Beike and Tsinghua University's Shenzhen Graduate School received a $12 million grant from the Shenzhen municipal government in 2007 to establish a laboratory for cell reprogramming and gene engineering studies, which will conduct research on stem cells, nuclear transfer and cellular reprogramming. |
| Shenzhen Chipscreen Biosciences | Two-year collaborative research service agreement with Roche R&D Center China (Shanghai) for high-throughput screening and proprietary chemical genomics-based discovery platform to screen and evaluate early-stage compounds provided by Roche center. |
| SinoCells Biotech | Agreements for use of facilities and clinical development products with both Peking University (Beijing) and Beijing Medical University (Beijing). |
| SinoGenoMax | Collaboration on biomarker identification with Beijing Medical Hospital (Beijing). |
| Sinovac Biotech | R&D partnerships with Institute of Laboratory Animal Science, Chinese Academy of Medical Science (Beijing), National Institute for the Control of Pharmaceutical and Biological Products (Beijing), National Institute for Viral Disease Control and Prevention, National Institute for Epidemic Disease, Chinese Center for Disease Control and Prevention (Beijing), and Department of Microbiology, University of Hong Kong (Hong Kong). |
| Tianjin SinoBiotech | R&D partnership with Peking University College of Life Sciences (Beijing). |
